Welcome to our dedicated page for Livanova news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova stock.
LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova (Nasdaq: LIVN) appointed Stefano Folli as incoming President, Cardiopulmonary, effective June 1, 2026, succeeding Franco Poletti, who retires July 31.
Folli joins the Executive Leadership Team, reporting to the CEO, and will oversee strategic growth of the nearly $800 million Cardiopulmonary business.
LivaNova (Nasdaq: LIVN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach on June 8, 2026, at 8:00 a.m. EDT. A live webcast and replay will be accessible via the LivaNova events webpage.
LivaNova (Nasdaq: LIVN) reported Q1 2026 revenue of $362.3M, up 14.3% reported and 11.1% constant-currency, with GAAP diluted EPS of $0.40 and adjusted diluted EPS of $0.98. The company raised full-year 2026 constant-currency revenue growth guidance to 7.0%–8.0% and adjusted diluted EPS to $4.20–$4.30. LivaNova received FDA PMA for the aura6000 System for moderate to severe obstructive sleep apnea and published 12‑month OSPREY trial results showing sustained pHGNS benefits.
LivaNova (Nasdaq: LIVN) reported 12-month OSPREY RCT results showing proximal hypoglossal nerve stimulation (pHGNS) produced clinically significant, durable improvements in obstructive sleep apnea (OSA).
In 104 adults, median AHI fell from 34.3 to 11.6 e/hr at month 7; ODI median dropped from 35 to 13 e/hr. FDA PMA for the aura6000 System was granted in March; commercial launch expected in 2027 pending a PMA supplement.
LivaNova (Nasdaq: LIVN) will release its first-quarter 2026 results and host a conference call on Wed., May 6, 2026 at 1:00 p.m. London time (8:00 a.m. EDT). The company will publish results before the call.
Investors can access an audiocast at www.livanova.com/events, join by phone using the listed U.S. and international numbers, or listen to a replay on the Investors section immediately after the event. Log on ~10 minutes early for setup. Conference access code: 946097.
LivaNova (Nasdaq: LIVN) received FDA premarket approval for the aura6000 System to treat adults with moderate to severe obstructive sleep apnea (AHI 15–65) who cannot tolerate or are ineligible for PAP therapy. The approval is supported by the OSPREY randomized controlled trial showing a 65% responder rate at 12 months and median AHI reduction from 34.3 to 11.6 events/hour at month 7. LivaNova plans a next‑generation, MRI‑compatible device with rechargeable battery tech targeting first‑half 2027 commercialization, pending FDA supplement review.
LivaNova (Nasdaq: LIVN) reported Q4 2025 revenue of $360.9M (+12.1% reported, +9.5% organic) and full-year 2025 revenue of $1.388B (+10.7% reported, +9.7% constant-currency). The company recorded a GAAP loss per share of $4.45 due to a $365.6M SNIA environmental liability, and adjusted EPS of $3.90. LivaNova issued 2026 guidance: constant-currency revenue growth of 6.0–7.0%, adjusted diluted EPS of $4.15–$4.25, and adjusted free cash flow of $160–$180M. CMS reimbursement for VNS Therapy increased materially, and FDA cleared the company’s cloud-based digital health platform.
LivaNova (Nasdaq: LIVN) will release its fourth-quarter and full-year 2025 results and host a conference call on Wed., Feb. 25, 2026 at 1:00 p.m. London time (8:00 a.m. ET). The company will issue results prior to the call and provide an audiocast at www.livanova.com/events. Telephone access is available at +1 833 470 1428 (U.S.) or +1 929 526 1599 (outside U.S.) using conference code 901145. Listeners are advised to log on ~10 minutes early. A replay will be posted on the Investors section of the LivaNova website immediately after the event.
LivaNova (Nasdaq: LIVN) announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco.
Vladimir Makatsaria, CEO, and Alex Shvartsburg, CFO, will participate in a fireside chat on Wed., Jan. 14, 2026 at 1:30 p.m. Pacific Standard Time. The session will be webcast; registered attendees can access it via www.livanova.com/events. Listeners are advised to log on ~10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) will present eight scientific posters at the American Epilepsy Society Annual Meeting (Dec 5-9, 2025) showcasing real-world evidence from the CORE-VNS study and new health-economics analyses.
Key findings include median seizure reductions up to 95% for the most disabling seizure types at 36 months, early seizure improvements in children by 3 months with sustained benefit to 36 months, a 94% median reduction when VNS was used after 2–3 anti-seizure medications versus 57% after >10 medications, and a >70% decrease in rescue medication use at 36 months. Analyses also report reduced hospitalizations, ED visits and overall costs post-implantation across commercial, Medicare, and Medicaid cohorts.